An international, multisite phase 3 trial published in the Lancet Neurology has found that continuous, 24-hour levodopa delivery through a subcutaneous infusion pump is safe and effective at reducing symptoms for longer periods of time. For the trial, 381 patients with Parkinson's disease in 16 countries were randomised to receive continuous subcutaneous infusion of levodopa, or oral levodopa.
Delivering levodopa through the infusion pump was safe and associated with almost two hours a day of additional “on” time when the medication is working and symptoms are controlled, compared with oral levodopa. The patients also performed better on four of nine other disease rating scales that looked at disability from Parkinson’s disease symptoms. The most common adverse events were reactions at the infusion site.
Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial
Dyskinesia: Lessons from Africa
